XLV - ETF AI Analysis
Top Page
Health Care Select Sector SPDR Fund (XLV)
Rating:73Outperform
Price Target:―
Positive Factors
Low Expense Ratio
The fund charges a relatively low fee, which helps investors keep more of their returns over time.
Large, Established Holdings
Many of the top positions are well-known, mature health care companies that have shown generally steady performance, which can add stability to the portfolio.
Targeted Health Care Exposure
The ETF provides focused access to the U.S. health care sector, which can be useful for investors who want specific exposure to this part of the market.
Negative Factors
Single-Sector Concentration
Almost all assets are in health care, so the fund can be hit hard if this sector faces regulatory or economic challenges.
Heavy Reliance on a Few Stocks
A small number of large holdings, such as Eli Lilly and Johnson & Johnson, make up a big share of the fund, increasing the impact if any of them perform poorly.
Recent Weak Year-to-Date Performance
The ETF and several of its largest holdings have shown weak results so far this year, which may concern investors looking for near-term strength.
XLV vs. SPDR S&P 500 ETF (SPY)
AUM37.69B
RegionNorth America
Expense Ratio0.08%
Beta0.49
IssuerSPDR
Inception DateDec 16, 1998
Dividend Yield1.72%
Asset ClassEquity
Index TrackedS&P Health Care Select Sector
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume8,341,693
30 Day Avg. Volume13,399,893
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
178.93Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering59
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XLV Summary
XLV is an ETF that follows the S&P Health Care Select Sector Index, giving you broad exposure to major U.S. healthcare companies. It holds well-known names like Johnson & Johnson and Merck, along with drug makers, medical device companies, and health insurers. Someone might invest in XLV to tap into the long-term growth and stability of the healthcare sector, which tends to be needed in all economic conditions and offers diversification away from tech or energy. A key risk is that it is heavily focused on healthcare, so its value can rise or fall with changes in that single sector.
How much will it cost me?The Health Care Select Sector SPDR Fund (XLV) has an expense ratio of 0.08%, meaning you’ll pay $0.80 per year for every $1,000 invested. This cost is lower than average because XLV is passively managed, tracking the Health Care Select Sector Index rather than relying on active stock picking.
What would affect this ETF?The XLV ETF, focused on the U.S. healthcare sector, could benefit from increasing demand for healthcare services driven by aging populations and advancements in medical technology. However, it may face challenges from regulatory changes, drug pricing pressures, or economic downturns that could impact healthcare spending. Its exposure to major companies like Johnson & Johnson and Pfizer provides stability but also ties its performance to the success of these key players.
XLV Top 10 Holdings
XLV is heavily tilted toward big U.S. drugmakers, with Eli Lilly, Johnson & Johnson, AbbVie, Merck, and Amgen setting the tone. Lately, Lilly and AbbVie have been losing steam, acting as a bit of a brake on the fund, while Merck and Amgen have been steadier hands. UnitedHealth has been a bright spot, giving the portfolio a lift from the managed-care side, even as tools and devices names like Thermo Fisher and Intuitive Surgical show more mixed, stop‑and‑go performance. Overall, it’s a concentrated bet on U.S. healthcare giants.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 13.50% | $5.14B | $835.18B | -1.03% | 72 Outperform | |
| Johnson & Johnson | 10.56% | $4.02B | $547.64B | 45.05% | 78 Outperform | |
| AbbVie | 6.77% | $2.58B | $351.47B | 2.62% | 66 Neutral | |
| UnitedHealth | 6.20% | $2.36B | $322.15B | -15.55% | 72 Outperform | |
| Merck & Company | 5.35% | $2.04B | $276.38B | 32.50% | 80 Outperform | |
| Amgen | 3.58% | $1.36B | $185.95B | 20.17% | 77 Outperform | |
| Thermo Fisher | 3.40% | $1.29B | $174.55B | 11.08% | 72 Outperform | |
| Intuitive Surgical | 3.30% | $1.26B | $170.78B | -8.37% | 78 Outperform | |
| Gilead Sciences | 3.12% | $1.19B | $161.86B | 20.13% | 78 Outperform | |
| Abbott Laboratories | 3.05% | $1.16B | $158.72B | -28.36% | 73 Outperform |
XLV Technical Analysis
Neutral
―
Price Trends
149.32
Negative
152.12
Negative
145.92
Positive
Market Momentum
-1.23
Positive
47.63
Neutral
27.05
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XLV, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 146.61, equal to the 50-day MA of 149.32, and equal to the 200-day MA of 145.92, indicating a neutral trend. The MACD of -1.23 indicates Positive momentum. The RSI at 47.63 is Neutral, neither overbought nor oversold. The STOCH value of 27.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XLV.
XLV Peer Comparison
Comparison Results
Performance Comparison
XLV
Health Care Select Sector SPDR Fund
145.99
9.89
7.27%
VGT
Vanguard Information Technology ETF
―
―
―
XLK
Technology Select Sector SPDR Fund
―
―
―
XLF
Financial Select Sector SPDR Fund
―
―
―
XLE
Energy Select Sector SPDR Fund
―
―
―
VHT
Vanguard Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents